Emerging engineered magnetic nanoparticulate probes for targeted MRI of atherosclerotic plaque macrophages

Nanomedicine

Volumn 7, Issue 5, 2012, Pages 735-749

  Kanwar, Rupinder K ^a   Chaudhary, Rajneesh ^b   Tsuzuki, Takuya ^b   Kanwar, Jagat R ^a  

^a Institute for Frontier Materials (IFM)   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

Author keywords

atherosclerosis; gadolinium; iron oxide nanoparticles; macrophages; molecular imaging; MRI

Indexed keywords

CELL SURFACE RECEPTOR; GADOLINIUM; MAGNETIC NANOPARTICLE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY;

ATHEROSCLEROTIC PLAQUE; CELL ACTIVITY; DRUG MONITORING; HEART INFARCTION; HUMAN; INFLAMMATION; MACROPHAGE; MOLECULAR IMAGING; NANOENGINEERING; NANOPROBE; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHAGOCYTE; PRIORITY JOURNAL; REVIEW; STROKE;

ANIMALS; CONTRAST MEDIA; FERRIC COMPOUNDS; GADOLINIUM; HUMANS; INFLAMMATION; MACROPHAGES; MAGNETIC RESONANCE IMAGING; METAL NANOPARTICLES; PLAQUE, ATHEROSCLEROTIC;

EID: 84861645988     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.46     Document Type: Review

References (73)

1. Kanwar RK, Kanwar JR, Wang D, Ormrod DJ, Krissansen GW. Temporal expression of heat shock proteins 60 and 70 at lesion-prone sites during atherogenesis in apoE-defcient mice. Arterioscler. Thromb. Vasc. Biol. 21(12), 1991-1997 (2001). (Pubitemid 34219752)
2. Narula J, Strauss HW. The popcorn plaques. Nat. Med. 13(5), 532-534 (2007). (Pubitemid 46828471)
3. Naghavi M, Libby P, Falk E et al. From vulnerable plaque to vulnerable patient: a call for new defnitions and risk assessment strategies: Part I. Circulation 108(14), 1664-1672 (2003). (Pubitemid 37243650)
4. Ross R. Atherosclerosis-an infammatory disease. N. Engl. J. Med. 340(24), 1928-1929 (1999).
5. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 6(7), 508-519 (2006). (Pubitemid 43980523)
6. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat. Immunol. 12(3), 204-212 (2011).
7. Erling F. Pathogenesis of atherosclerosis. J. Am. Coll. Cardiol. 47(Suppl. 8), C7-C12 (2006).
8. Douglas G, Channon KM. The pathogenesis of atherosclerosis. Medicine 38(8), 397-402 (2010).
9. Hansson GK. Infammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352(16), 1685-1695 (2005).
10. Mclaren JE, Michael DR, Ashlin TG, Ramji DP. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog. Lipid Res. 50(4), 331-347 (2011).
11. Packard RR, Libby P. Infammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin. Chem. 54(1), 24-38 (2008). (Pubitemid 351182593)
12. Gimbrone MA, Topper JN, Nagel T, Anderson KR, Garcia-Cardeña G. Endothelial dysfunction, hemodynamic forces, and atherogenesisa. Ann. N.Y. Acad. Sci. 902(1), 230-240 (2000). (Pubitemid 30389128)
13. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice defcient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc. Natl Acad. Sci. USA 92(18), 8264-8268 (1995).
14. Greaves DR, Gordon S. The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges. J. Lipid Res. 50(Suppl.), S282-S286 (2009).
15. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, infammation, and atherosclerosis. Pharmacol. Rev. 58(3), 342-374 (2006). (Pubitemid 44394906)
16. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson G. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arterioscler. Thromb. Vasc. Biol. 6(2), 131-138 (1986). (Pubitemid 16024121)
17. Kanwar JR, Kanwar RK, Burrow H, Baratchi S. Recent advances on the roles of NO in cancer and chronic infammatory disorders. Curr. Med. Chem. 16(19), 2373-2394 (2009).
18. Choudhury RP, Fisher EA. Molecular imaging in atherosclerosis, thrombosis, and vascular infammation. Arterioscler. Thromb. Vasc. Biol. 29(7), 983-991 (2009).
19. Rudd JH, Hyafl F, Fayad ZA. Infammation imaging in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 29(7), 1009-1016 (2009).
20. Jaffer FA, Libby P, Weissleder R. Molecular and cellular imaging of atherosclerosis: emerging applications. J. Am. Coll. Cardiol. 47(7), 1328-1338 (2006).
21. Owen DRJ, Lindsay AC, Choudhury RP, Fayad ZA. Imaging of atherosclerosis. Annu. Rev. Med. 62(1), 25-40 (2011).
22. Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature 451(7181), 953-957 (2008). (Pubitemid 351305938)
23. Kubo T, Imanishi T, Takarada S et al. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J. Am. Coll. Cardiol. 50(10), 933-939 (2007). (Pubitemid 47313602)
24. Makowski MR, Wiethoff AJ, Blume U et al. Assessment of atherosclerotic plaque burden with an elastin-specifc magnetic resonance contrast agent. Nat. Med. 17(3), 383-388 (2011).
25. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 17(5), 545-580 (2003). (Pubitemid 36307540)
26. Weissleder R, Mahmood U. Molecular imaging. Radiology 219(2), 316-333 (2001). (Pubitemid 32336342)
27. John VF. In vivo near-infrared fuorescence imaging. Curr. Opin. Chem. Biol. 7(5), 626-634 (2003).
28. Phelps ME. PET: the merging of biology and imaging into molecular imaging. J. Nucl. Med. 41(4), 661-681 (2000). (Pubitemid 30207744)
29. Hashemi RH, Bradley WG, Lisanti CJ. MRI: The Basics. Lippincott Williams and Wilkins, NY, USA (2004).
30. Na HB, Song IC, Hyeon T. Inorganic nanoparticles for MRI contrast agents. Adv. Mater. 21(21), 2133-2148 (2009).
31. Briley-Saebo KC, Mulder WJM, Mani V et al. Magnetic resonance imaging of vulnerable atherosclerotic plaques: current imaging strategies and molecular imaging probes. J. Magn. Reson. Imaging 26(3), 460-479 (2007). (Pubitemid 350194567)
32. Fayad ZA, Fuster V, Fallon JT et al. Noninvasive in vivo human coronary artery lumen and wall imaging using black-blood magnetic resonance imaging. Circulation 102(5), 506-510 (2000). (Pubitemid 30639967)
33. Maintz D, Ozgun M, Hoffmeier A et al. Selective coronary artery plaque visualization and differentiation by contrast-enhanced inversion prepared MRI. Eur. Heart J. 27(14), 1732-1736 (2006). (Pubitemid 44025361)
34. Chen W, Cormode DP, Fayad ZA, Mulder WJM. Nanoparticles as magnetic resonance imaging contrast agents for vascular and cardiac diseases. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 3(2), 146-161 (2011).
35. Hahn M, Singh A, Sharma P, Brown S, Moudgil B. Nanoparticles as contrast agents for in-vivo bioimaging: current status and future perspectives. Anal. Bioanal. Chem. 399(1), 3-27 (2011).
36. Ohgushi M, Nagayama K. Dextrandextran-magnetite: a new relaxation reagent and its application to T2 measurements in gel systems. J. Magn. Reson. 29(3), 599-601 (1978).
37. Yx W. Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant. Imaging Med. Surg. 1, 35-40 (2011).
38. Winter P, Caruthers S, Lanza G, Wickline S. Quantitative cardiovascular magnetic resonance for molecular imaging. J. Cardiovasc. Magn. R. 12(1), 62 (2010).
39. Wickline SA, Neubauer AM, Winter PM, Caruthers SD, Lanza GM. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J. Magn. Reson. Imaging 25(4), 667-680 (2007). (Pubitemid 46516717)
40. Liao Z, Wang H, Wang X et al. Biocompatible surfactin-stabilized superparamagnetic iron oxide nanoparticles as contrast agents for magnetic resonance imaging. Colloids Surf. A: Physicochem. Eng. Asp. 370(1-3), 1-5 (2010).
41. 3 nanoparticles. J. Alloys Compd. 509(17), 5420-5425 (2011).
42. Maeng JH, Lee D-H, Jung KH et al. Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer. Biomaterials 31(18), 4995-5006 (2010).
43. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur. Radiol. 11(11), 2319-2331 (2001). (Pubitemid 33041104)
44. Taupitz M, Schnorr J, Abramjuk C et al. New generation of monomer-stabilized very small superparamagnetic iron oxide particles (VSOP) as contrast medium for MR angiography: preclinical results in rats and rabbits. J. Magn. Reson. Imaging 12(6), 905-911 (2000).
45. Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 103(3), 415-422 (2001). (Pubitemid 32105982)
46. Schmitz SA, Coupland SE, Gust R et al. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest. Radiol. 35(8), 460-471 (2000). (Pubitemid 30622013)
47. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 175(2), 489-493 (1990). (Pubitemid 20135290)
48. Kooi ME, Cappendijk VC, Cleutjens KBJM et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 107(19), 2453-2458 (2003). (Pubitemid 36605228)
49. Tang TY, Howarth SPS, Miller SR et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) study: evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J. Am. Coll. Cardiol. 53(22), 2039-2050 (2009).
50. Fayad ZA, Razzouk L, Briley-Saebo KC, Mani V. Iron oxides magnetic resonance imaging for atherosclerosis therapeutic evaluation: still 'rusty?'. J. Am. Coll. Cardiol. 53, 2051-2052 (2009).
51. Terashima M, Uchida M, Kosuge H et al. Human ferritin cages for imaging vascular macrophages. Biomaterials 32(5), 1430-1437 (2011).
52. Kosuge H, Sherlock SP, Kitagawa T et al. FeCo/graphite nanocrystals for multi-modality imaging of experimental vascular infammation. PLoS One 6(1), e14523 (2011).
53. Seo WS, Lee JH, Sun X et al. FeCo/graphitic-shell nanocrystals as advanced magnetic-resonance-imaging and near-infrared agents. Nat. Mater. 5(12), 971-976 (2006). (Pubitemid 44847494)
54. Maiseyeu A, Mihai G, Kampfrath T et al. Gadolinium-containing phosphatidylserine liposomes for molecular imaging of atherosclerosis. J. Lipid Res. 50(11), 2157-2163 (2009).
55. Maiseyeu A, Mihai G, Roy S et al. Detection of macrophages via paramagnetic vesicles incorporating oxidatively tailored cholesterol ester: an approach for atherosclerosis imaging. Nanomedicine 5(9), 1341-1356 (2010).
56. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl Acad. Sci. USA 76(1), 333-337 (1979). (Pubitemid 9110191)
57. Lipinski MJ, Amirbekian V, Frias JC et al. MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn. Reson. Med. 56(3), 601-610 (2006). (Pubitemid 44338879)
58. Amirbekian V, Lipinski MJ, Briley-Saebo KC et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc. Natl Acad. Sci. USA 104(3), 961-966 (2007). (Pubitemid 46154719)
59. Mulder WJM, Strijkers GJ, Briley-Saboe KC et al. Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magn. Reson. Med. 58(6), 1164-1170 (2007). (Pubitemid 350234203)
60. Lipinski MJ, Frias JC, Amirbekian V et al. Macrophage-specifc lipid-based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis. JACC: Cardiovasc. Imaging 2(5), 637-647 (2009).
61. Fitzgerald ML, Mujawar Z, Tamehiro N. ABC transporters, atherosclerosis and infammation. Atherosclerosis 211(2), 361-370 (2010).
62. Skajaa T, Cormode DP, Falk E, Mulder WJ, Fisher EA, Fayad ZA. High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 30(2), 169-176 (2010).
63. Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specifc contrast agent for MRI of atherosclerotic plaques. J. Am. Chem. Soc. 126(50), 16316-16317 (2004). (Pubitemid 40081918)
64. Frias JC, Ma Y, Williams KJ, Fayad ZA, Fisher EA. Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett. 6(10), 2220-2224 (2006). (Pubitemid 44663808)
65. Cormode DP, Briley-Saebo KC, Mulder WJM et al. An apoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection. Small 4(9), 1437-1444 (2008).
66. Chen W, Vucic E, Leupold E et al. Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol. Imaging 3(6), 233-242 (2008).
67. Sauer I, Nikolenko H, Keller S, Abu Ajaj K, Bienert M, Dathe M. Dipalmitoylation of a cellular uptake-mediating apolipoprotein E-derived peptide as a promising modifcation for stable anchorage in liposomal drug carriers. BBA-Biomembranes 1758(4), 552-561 (2006). (Pubitemid 43767724)
68. Cormode DP, Skajaa T, Van Schooneveld MM et al. Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano. Lett. 8(11), 3715-3723 (2008).
69. Yamakoshi Y, Qiao H, Lowell AN et al. LDL-based nanoparticles for contrast enhanced MRI of atheroplaques in mouse models. Chem. Commun. 47(31), 8835-8837 (2011).
70. Li D, Patel AR, Klibanov AL et al. Molecular imaging of atherosclerotic plaques targeted to oxidized LDL receptor LOX-1 by SPECT/CT and magnetic resonance/clinical perspective. Circ. Cardiovasc. Imaging 3(4), 464-472 (2010).
71. Briley-Saebo KC, Shaw PX, Mulder WJM et al. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specifc epitopes. Circulation 117(25), 3206-3215 (2008).
72. Te Boekhorst BC, Bovens SM, Hellings WE et al. Molecular MRI of murine atherosclerotic plaque targeting NGAL: a protein associated with unstable human plaque characteristics. Cardiovasc. Res. 89(3), 680-688 (2011).
73. Chen IY, Wu JC. Cardiovascular molecular imaging. Circulation 123(4), 425-443 (2011).